Literature DB >> 7909979

Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies.

E N Harris1, S Pierangeli, D Birch.   

Abstract

An anticardiolipin wet workshop was conducted at the Fifth International Antiphospholipid Symposium (San Antonio, Texas, September 9-12, 1992). The workshop had four objectives: 1. to determine variability in measurement of immunoglobulin (Ig) G, IgM, and IgA anticardiolipin of eight unknown sera; 2. to examine the correlation between three commercial enzyme-linked immunosorbent assay (ELISA) kits and the Antiphospholipid Standardization Laboratory; 3. to examine protocols by which anticardiolipin binding to phospholipid antigens and beta 2 glycoprotein 1 (beta 2GP1) might be compared; and 4. to examine the beta 2GP1 effect on cardiolipin binding activity. Results showed good overall correlation of quantitative anticardiolipin measurements between workshop participants and the Antiphospholipid Standardization Laboratory. Correlation with individual ELISA kits was also good. With respect to the third objective, all participants showed comparable binding to cardiolipin and phosphatidylserine but none to phosphatidylcholine or beta 2GP1. Finally, beta 2GP1 enhanced, but was not essential for, anticardiolipin binding. This workshop will not settle controversies about anticardiolipin measurement and specificity, but suggests protocols to resolve these issues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909979     DOI: 10.1093/ajcp/101.5.616

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

1.  A decrease in antiphospholipid antibodies before a thrombotic event.

Authors:  S Praprotnik; B Bozic
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

2.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

Authors:  S Hörkkö; E Miller; E Dudl; P Reaven; L K Curtiss; N J Zvaifler; R Terkeltaub; S S Pierangeli; D W Branch; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.

Authors:  Iñigo Les; Naiara Parraza; Pilar Anaut; Saioa Eguiluz; Cristina Sánchez; María Enriqueta Preciado; Jesús Ángel Loza; Ander Andía
Journal:  Rheumatol Int       Date:  2017-11-10       Impact factor: 2.631

Review 4.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Differences in functional activity of anticardiolipin antibodies from patients with syphilis and those with antiphospholipid syndrome.

Authors:  S S Pierangeli; G H Goldsmith; S Krnic; E N Harris
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

Review 6.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

7.  Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss.

Authors:  A E Tebo; T D Jaskowski; H R Hill; D W Branch
Journal:  Clin Exp Immunol       Date:  2008-09-23       Impact factor: 4.330

8.  An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Authors:  Josh D Nelson; Florence M Brunel; Richard Jensen; Emma T Crooks; Rosa M F Cardoso; Meng Wang; Ann Hessell; Ian A Wilson; James M Binley; Philip E Dawson; Dennis R Burton; Michael B Zwick
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

9.  Penile alterations with severe sperm abnormalities in antiphospholipid syndrome associated with systemic lupus erythematosus.

Authors:  Carlos Nobre Rabelo-Júnior; Eloisa Bonfá; Jozélio F Carvalho; Marcello Cocuzza; Osmar Saito; Carmita H Abdo; Clovis A Silva
Journal:  Clin Rheumatol       Date:  2012-09-11       Impact factor: 2.980

10.  Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.

Authors:  E I B Peerschke; W Yin; D R Alpert; R A S Roubey; J E Salmon; B Ghebrehiwet
Journal:  Lupus       Date:  2009-05       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.